Condition: Solid Tumor · Sponsor: PAQ Therapeutics, Inc.
The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutated advanced solid tumors as monotherapy.
This description comes directly from the study's public registry record.
PAQ Therapeutics · 781-819-2949 · ClinicalTrials@paqtx.com
Always discuss trial participation with your own doctor first.
| Dana Farber/Massachusetts General Hospital, Inc | Boston, Massachusetts, United States | Recruiting |
| SCRI Lake Mary | Nashville, Tennessee, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| New Experimental Therapeutics of San Antonio LLC | San Antonio, Texas, United States | Recruiting |
| START - South Texas Accelerated Research Therapeutics, LLC | San Antonio, Texas, United States | Recruiting |
| START Mountain Region | West Valley City, Utah, United States | Recruiting |
| NEXT Virginia | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06797336